Practice

Latest News

ibd | Image credit: eddows - stock.adobe.com
Patients With IBD Maintain Therapy 2 Years Post-Switching to Infliximab Biosimilar

March 23rd 2025

People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.

Psoriasis. | Image Credit: Егор Кулинич - stock.adobe.com
Psoriasis Biosimilars Saved VA $67 Million in 2023

February 12th 2025

Elie Bahou, MD, PhD
How Vertical Integration Drives Innovation and Access in Biosimilars

December 27th 2024

Elie Bahou, MD, PhD
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access

December 22nd 2024

doctor talking to patient | Image credit: New Africa - stock.adobe.com
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching

December 18th 2024

© 2025 MJH Life Sciences

All rights reserved.